Meeting Coverage

Meeting Coverage

video

Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML

Monotherapy with vadastuximab talirine led to high response rates in older patients with acute myeloid leukemia who are considered unfit for intensive chemotherapy. Dr....
video

Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma Patients

Heavily-refractory myeloma patients who have exhausted available treatment agents were able to achieve a response with the investigational agent selinexor. Dr. Vogl shares results...
video

Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL

Dr. Schrappe discusses results of the AIEOP-BFM ALL 2000 trial, presented as a plenary abstract at the 2016 ASH Annual Meeting.
video

Mogamulizumab May Be Effective in Relapsed/Refractory T-Cell Leukemia

Adrienne A. Phillips, MD, MPH, shares results seen with mogamulizumab in the largest randomized clinical trial of relapsed/refractory T-cell leukemia to date.
video

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still...
video

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid...
video

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with...
video

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
video

Study Finds Thrombosis Risk Changes Throughout Myeloma Disease Course

Brea Lipe, MD, discusses the risk of venous thromboembolism in patients with myeloma – and whether thromboprophylaxis guidelines need to be changed.
video

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.